Orchestra BioMed Holdings, Inc. (OBIO): R&D Expense

Annual figures by period end, from SEC filings.

$58.19M
Year ended 2025-12-31
$63.22M
Trailing 12 months to 2026-06-30
+38.4%
3-year compound annual growth
2022-12-31: $21.95M2023-12-31: $33.82M2024-12-31: $42.80M2025-12-31: $58.19M$58.19M
2022-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$58.19M+35.9%2026-03-12, From 2025-01-01
2024-12-31$42.80M+26.6%2026-03-12, From 2024-01-01
2023-12-31$33.82M+54.1%2025-03-31, From 2023-01-01
2022-12-31$21.95Mn/a2024-03-27, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Orchestra BioMed Holdings, Inc. (OBIO)2025-12-31$58.19M+35.9%
ClearPoint Neuro, Inc. (CLPT)2025-12-31$13.90M+12.1%
Retractable Technologies Inc (RVP)2025-12-31$675.6K+0.2%
Utah Medical Products Inc (UTMD)2025-12-31$668.0K-17.8%
Interpace Biosciences, Inc. (IDXG)2025-12-31$642.0K-5.0%
Sensus Healthcare, Inc. (SRTS)2025-12-31$7.78M+84.5%
KORU Medical Systems, Inc. (KRMD)2025-12-31$4.39M-16.6%
SS Innovations International, Inc. (SSII)2025-12-31$3.69M+47.9%
SANUWAVE Health, Inc. (SNWV)2025-12-31$1.35M+101.0%

Compare OBIO, CLPT, RVP, UTMD side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗